-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Downgrades Forte Biosciences to Equal-Weight, Raises Price Target to $77

Benzinga·07/28/2026 10:52:54
語音播報
Barclays analyst Etzer Darout downgrades Forte Biosciences (NASDAQ:FBRX) from Overweight to Equal-Weight and raises the price target from $74 to $77.